Autoantibodies are one of the least explored records in human biology. They often appear years before clinical disease, across cancer, autoimmune disorders, infection, and aging. But one antibody signal from one study says little by itself. It only becomes meaningful when it’s measured the same way every time and compared against a large, well-characterized population.
ImmunoINSIGHTS™ exists to make that possible. We profile autoantibodies against 1,920 clinically relevant antigens using standardized, reproducible assays, then compare every result with a reference set of more than 10,000 immune profiles. Our work builds on a decade of experience across 30,000+ patient samples and more than 25 drug development programs and runs on Alden Scientific’s platform. We help scientists, clinicians, and drug developers turn immune signals into biomarkers that hold up across studies. That means earlier detection, more precise patient stratification, and better decisions from discovery through clinical development.